TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 2 months to \< 18 years old.~* Presence of CABP requiring hospitalization and IV antibacterial therapy~Exclusion Criteria:~* Documented history of any hypersensitivity of allergic reaction to any β-lactam antimicrobial.~* Confirmed or suspected infection with a pathogen known to be resistant to ceftriaxone.~* Confirmed or suspected respiratory tract infection attributed to sources other than CABP pathogens.~* Non-infectious causes of pulmonary infiltrates.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Ceftaroline fosamil (Type: EXPERIMENTAL): None
- Ceftriaxone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of idiopathic PD as defined by the United Kingdom Parkinson's Disease Society Brain Bank Criteria~2. Hoehn and Yahr stage of 2 to 4 in the on state~3. Excessive daytime sleepiness as defined by the Epworth Sleepiness Scale (ESS) score of greater than or equal to 12 points~4. Stable PD medication regimen for at least 4 weeks prior to study screening~5. Willing and able to give written informed consent~Exclusion Criteria:~1. Atypical parkinsonian syndromes~2. Significant sleep disordered breathing (defined as an apnea-hypopnea index \>15 events/hr of sleep on screening PSG)~3. Significant periodic limb movement disorder (defined as a PLM arousal index\>10 events/hr of sleep on screening PSG) and REM sleep behavior disorder (based on the presence of both clinical symptomatology as well as intermittent loss of REM atonia on screening PSG)~4. Cognitive impairment indicated by the mini-mental status examination (MMSE) score of less than 24~5. Presence of depression defined as the Beck Depression Inventory (BDI) score \>14~6. Untreated hallucinations or psychosis (drug-induced or spontaneous)~7. Use of hypno-sedative drugs for sleep or stimulants during the daytime~8. Use of antidepressants unless the patient has been on a stable dose for at least three months~9. Visual abnormalities that may interfere with light therapy, such as significant cataracts, narrow angle glaucoma or blindness~10. Travel through 2 time zones within 90 days prior to study screening

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bright White (Type: ACTIVE_COMPARATOR): Exposure to bright white light treatment.
- Dim red light (Type: PLACEBO_COMPARATOR): Exposure to dim red light treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adult subjects, age 18 to 55 years old~* able to understand procedures, agree to participate and willing to give informed consent~Exclusion Criteria:~* history of any significant disease~* use of any medication 7 days prior to start of study~* participation in a clinical trial within 30 days of start of study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Hercules: 8 mg/kg i.v. infusion over 90 minutes
- Treatment B (Type: ACTIVE_COMPARATOR): Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
- Treatment C (Type: ACTIVE_COMPARATOR): Herceptin US: 8 mg/kg i.v. infusion over 90 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Children With Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven neuroblastoma or maturing ganglioneuroma that is judged to be intermediate risk by one of the following criteria:~  * International Neuroblastoma Staging System (INSS) stage III~    * Under 1 year old, MYCN oncogene nonamplified, and any ploidy~   * 1 to 20 years old, MYCN nonamplified, favorable Shimada histology~ * INSS stage IV~    * Under 1 year old, MYCN nonamplified, any ploidy~ * INSS stage IVS~    * Under 1 year old, MYCN nonamplified, unfavorable Shimada histology and any ploidy OR favorable Shimada histology and diploidy~* All patients must be registered on the companion neuroblastoma biology study (COG-ANBL00B1)~PATIENT CHARACTERISTICS:~Age:~* Under 21~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No abnormal organ function that would prohibit chemotherapy unless due to neuroblastoma~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Prior chemotherapy for patients with intradural extension and emergent paresis allowed provided biopsy was performed within 96 hours after treatment~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No other prior therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): See detailed description.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) diagnosis of schizophrenia or schizoaffective disorder~* Taking a stable dose of olanzapine for at least 30 days~* Have not experienced an acute exacerbation of their psychotic symptoms in the preceding 3 months~* Either had only a marginal clinical response to olanzapine, or had unacceptable side effects related to weight gain including obesity, diabetes or abnormal glucose metabolism~Exclusion Criteria:~* Patients with a history of treatment failure with, or significant adverse events attributable to, risperidone, or known sensitivity to risperidone~* A history of antipsychotic therapy other than olanzapine in the 30 days preceding randomization~* Presence of serious or unstable illnesses: liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric or metabolic disturbances~* Diagnosis of substance dependence~* Pregnant or nursing female, or those lacking adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mindful Stress Reduction in Diabetes Self-management Education for Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Referral to DSME class at VA Pittsburgh Healthcare System University Drive Campus (VAPHS UD)~* Diagnosis of type 1 or type 2 diabetes~* Hemoglobin A1C \>7.0%~* Problem Areas in Diabetes Scale (PAID) -5 score =/ \>3 or Diabetes Distress Scale -2 =/\>2 score indicating the presence of Diabetes-related Distress~Exclusion Criteria:~* Documented cognitive impairment that would interfere with the ability to comprehend the informed consent and actively participate in the study~* Previous attendance of VA DSME class within the past 12 months~* Currently active mindfulness practice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diabetes Self Management Education (DSME) + Mind-STRIDE (Type: EXPERIMENTAL): Will receive routine diabetes self-management education + the Mind-STRIDE intervention
- DSME alone (Type: NO_INTERVENTION): Usual care control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented osteoporosis of the femoral neck and lumbar spine~Exclusion Criteria:~* BMI greater than or equal to 35

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
- Risedronate (Type: EXPERIMENTAL): 35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require at least 6 hours of continuous IV sedation.~2. Age: subjects must fit the following age range at screening:~   Preterm subjects ≥28 weeks through \<36 weeks, gestational age;~   Note: Gestational age (in weeks) will be calculated as follows: the time elapsed between the first day of the last menstrual period and the day of enrollment.~3. Weight: subject's weight at the time of enrollment must be \>1000 g.~4. Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the informed consent document approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).~Exclusion Criteria:~1. Neonate subjects with neurological conditions that prohibit an evaluation of sedation such as:~   * Diminished consciousness from increased intracranial pressure.~  * The presence of catastrophic brain injury or other severe mental disorders that would make responses to sedatives unpredictable and/or measurement of the N-PASS unreliable.~  * Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking (NMB) agents.~2. Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires are in situ.~   Note: If subject's status-post Cardio Pulmonary Bypass (CPB) was managed without pacing wires in situ, the subject must not be suspected to be in second degree or third degree heart block at the time of DEX administration.~3. HR \< 120 bpm prior to the initiation of DEX.~4. Exposure to any investigational drug within 30 days prior to DEX administration.~5. Previous exposure to DEX as part of an investigational study.~6. In subjects that are ex-utero for less than 72 hours, a maternal history of poly-substance drug abuse, based upon the Investigator's clinical judgment.~7. At the discretion of the Investigator, subjects in whom the risk of DEX treatment is expected to exceed its benefits.~8. Subjects who have a known allergy or contraindication to fentanyl, morphine, MDZ, DEX, or other α-2 agonists.~9. Requirement for medications other than DEX, MDZ, morphine, or fentanyl for sedation and pain control.~10. Screening ALT levels \>115 U/L.

- Gender: ALL
- Minimum Age: 28 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention and Treatment of Immersion Pulmonary Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of immersion pulmonary edema~Exclusion Criteria:~* Coronary artery disease, cardiomyopathy, heart valve disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Sildenafil (Type: EXPERIMENTAL): Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV+~2. Age 18 or over~3. Able to read and respond in English~4. Reside within the US~5. Willing to participate in an online survey.~Exclusion Criteria:~1. HIV-negative~2. under age 18~3. Unwilling to provide key data (i.e., age, information about symptoms) on the online survey.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): VIP app that delivers HIV-related symptom strategies
- Control (Type: SHAM_COMPARATOR): VIP app without HIV-related symptom strategies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Male and non-pregnant female subjects seeking outpatient treatment for opioid dependence with physiological features without serious medical or psychiatric disorders.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for all study participants:~* Right-Handedness~Exclusion Criteria for all study participants:~* Any clinically significant history of cardiac problems~* Any current Axis I psychiatric diagnosis as verified by the Structured Clinical Interview for DSM-IV (other than participants with ADHD or history of alcohol dependence)~* A previous adequate trial with methylphenidate (Ritalin) or naltrexone (ReVia)~* Currently taking any psychoactive medications~* Any clinically significant medical condition~* Any clinically significant neurological problem (seizures, tics, serious head injury)~* Contraindications to MRI (metal objects in body or claustrophobia)~* Currently pregnant or lactating~* Alcohol or substance abuse (current or in the past 2 years)~* Left-handedness or ambidextrous~* Liver or kidney disease~Inclusion Criteria for the participants with ADHD:~* Currently un-medicated adults with ADHD~* Has met full DSM-IV-R criteria (at least six of nine symptoms)for inattentive or hyperactive/impulsive subtypes (or both) by age 7 as well within the past month~* Has described a chronic course of ADHD symptomatology from childhood to adulthood~* Has endorsed a moderate or severe level of impairment attributed to the ADHD symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (Type: EXPERIMENTAL): Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
- Adult Attention-Deficit/Hyperactivity Disorder (Type: EXPERIMENTAL): ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* A male or female of 7 to 8 years of age (from and including the 7th birthday up to but excluding the 9th birthday) at the time of enrolment.~* With documented evidence of previous vaccination with three consecutive doses of Engerix™-B in Germany~* Written informed consent obtained from the parents or guardians of the subject at the time of enrolment.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product~* Evidence of previous hepatitis B booster vaccination since administration of the third dose of Engerix™-B vaccine.~* History of or intercurrent hepatitis B disease.~* Hepatitis B vaccination at birth.~* Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before HBV vaccine challenge and ending 30 days after.~* Administration of immunoglobulins and/or any blood products within the three months preceding HBV vaccine challenge or planned administration during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the HBV vaccine challenge.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- Group Engerix (Type: EXPERIMENTAL): Subjects received a single challenge dose of Engerix™ (hepatitis-B \[HBV\] vaccine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Considered healthy after undergoing a clinical evaluation;~* Agree freely and sign the Recruitment and Informed Consent Term, after all the content of the protocol was clear before any procedure;~* Present the body mass index greater than 19 and less than 30.~Exclusion Criteria:~* Results of laboratory tests outside the range considered normal, unless they were considered clinically irrelevant;~* Allergic to lamivudine or any other drug;~* Positive outcome of the pre-admission pregnancy test;~* Regular medication within four (4) weeks prior to the start of the study or use of any medication to present interaction with lamivudine one week before the start of the study;~* Use abusive alcoholic beverage;~* Use of illicit drugs and tobacco;~* History of liver disease, renal, pulmonary, gastrointestinal, epileptic, hematologic or psychiatric; hypo- or hypertension of any cause that required pharmacological treatment; myocardial infarction, angina and / or heart failure;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Period 1 (Type: ACTIVE_COMPARATOR): Epivir ® tablet 150-mg single dose (drug reference)
- Period 2 (Type: EXPERIMENTAL): Lamivudine 150-mg tablet single dose (drug test)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete